<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	(Jindo Laboratories, Japan)	
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	2.5/the 100 line	-
Provide accession number in repository OR		
supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of	2.5/the 100 line	
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	This study will explore in Laboratory animals	n/a
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the	This study will explore in Laboratory animals	n/a
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	This study will explore in Laboratory animals	n/a
in repository (where relevant) OR RRID		
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	This study did not include Plants and microbes	n/a
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique	This study did not include Plants and microbes	n/a
accession number if available, and source		
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	This study did not include Human research participants	n/a
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	This study did not include Human research participants	n/a
obtained from study participants.		
Report on age and sex for all study participants.	This study did not include Human research participants	n/a

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	This study did not include clinical trials	n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	This study did not include Laboratory protocol	n/a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.	This study did not include these statistics details	
Sample size determination	This study did not include these statistics details	
Randomisation	This study did not include these statistics details	
Blinding	This study did not include these statistics details	
Inclusion/exclusion criteria	This study did not include these statistics details	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Three times	,u
Define whether data describe technical or biological replicates	yes	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This study did not include Ethics	n/a
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This study did not include Ethics	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	This study did not include Ethics	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	There is no Dual Use Research of Concern (DURC)	n/a

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	We used cell lines to do this study.	n/a
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	2.8/the 126 line	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		
If data are publicly available, provide accession number in repository or DOI or URL.		
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	2.1/the 61 line	
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		
If code is publicly available, provide accession number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of	Section Acknowledgement.	
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/TCR-20-2808